Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01596673 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users
A Phase 1 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01596673 is a Phase 1 study that has completed, run by Cephalon. The registered enrollment target is 100 participants.
The verdict
NCT01596673, a Phase 1 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative abuse potential of the hydrocodone bitartrate extended-release tablet compared to immediate-release hydrocodone bitartrate.
Interventions
- DRUG Placebo
- DRUG 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01596673
The ClinicalTrials.gov registry entry for NCT01596673 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01596673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01596673 about?
NCT01596673 is a clinical study titled "A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users". The purpose of this study is to assess the relative abuse potential of the hydrocodone bitartrate extended-release tablet compared to immediate-release hydrocodone bitartrate.
What is the current status of trial NCT01596673?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2012-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01596673?
The interventions under investigation include: Placebo (DRUG), 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact) (DRUG).
Who is sponsoring clinical trial NCT01596673?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.